AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Caracterization of the Combined Alterations in Respiration and aROUSal in Patients With Drug-resistant EpiLepsy

RecruitingNAAges 18 Years - 55 YearsAllHospices Civils de Lyon
💬

In plain words

What the trial is, and whether it could suit you

30% of patients with epilepsy suffer from drug-resistant seizures and are at risk of epilepsy-related complications, from cognitive dysfunctions to premature mortality. Both seizures and their complications are modulated by patients' vigilance states, with a tight and bi-directional interplay between sleep and epilepsy. Several epilepsy complications are associated with sleep, such as sleep-disordered breathing or Sudden and Unexpected Death in Epilepsy (SUDEP). SUDEP is a non-traumatic death, unrelated to a documented status epilepticus, which accounts for up 50% of premature deaths in epilepsy, with a cumulative risk of ≈ 10% at 40 years in patients with childhood-onset epilepsy. SUDEP typically occurs during sleep, after a nocturnal seizure, and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS), suggesting that int

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: Patients : 1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study 2. Aged 18 to 55 years old 3. Diagnosis of focal epilepsy 4. Epilepsy is refractory to treatment, as defined by the International League Against Epilepsy 5. Patients with ≥3 focal to bilateral tonic-clonic seizure (FBTCS) during the past 18 months 6. Patients who had undergone long-term video-EEG (VEEG) monitoring for presurgical evaluation in the past ten years within the Department of Functional Neurology and Epileptology at Hospices Civils de Lyon, ensuring access to detailed information about: * occurrence of transient respiratory dysfunction during the focal seizures, transient hypoxemia during strictly focal seizures being observed in 40% of patients(39) and in 87% of patients with at least one FBTCS during the VEEG monitoring(46) * localization of the epileptogenic zone, the risk of peri-ictal respiratory dysfunction being greater in seizures of temporal lobe origin than in extra-temporal seizures, even after FBTCS Healthy subjects 1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study 2. Aged 18 to 55 years old Exclusion Criteria: Patients 1. Ongoing or chronic respiratory and/or cardiac insufficiency 2. Obstructive sleep-apnea syndrome 3. Ongoing treatment with selective serotonin reuptake inhibitor 4. Patient treated with vagal nerve stimulation 5. Pregnant women or breastfeeding women, based on declarations at V0 6. Persons receiving psychiatric care 7. Persons deprived of their liberty by a judicial or administrative decision 8. Adults subject to a legal protection measure (guardianship, curatorship) 9. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme 10. Positive urine pregnancy test at V1, if applicable Healthy subjects 1. History of epilepsy 2. Ongoing or chronic respiratory and/or cardiac insufficiency 3. Obstructive sleep-apnea syndrome 4. Pregnant women, women in labor or breastfeeding women, based on declarations at V0 5. Persons receiving psychiatric care 6. Persons deprived of their liberty by a judicial or administrative decision 7. Adults subject to a legal protection measure (guardianship, curatorship) 8. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme 9. Positive urine pregnancy test at V1, if applicable
💊

What it tests

  • Video-EEG monitoring
  • Respiratory monitoring and polysomnography
  • 1 Hypercapnic challenge while participant is awake
  • 2 Hypercapnic challenges while participant is sleeping
  • Auditory stimulus
📍

Where

1 site
Hôpital Pierre Wertheimer
Bron, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy